This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: June 12, 2012
Last updated: March 24, 2016
Last verified: March 2016
The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.

Condition Intervention Phase
Type 2 Diabetes Drug: Saxagliptin Drug: Dapagliflozin Drug: Metformin IR Drug: Placebo matching with Saxagliptin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy With Saxagliptin Added to Dapagliflozin in Combination With Metformin Compared to Therapy With Placebo Added to Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Dapagliflozin

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 [ Time Frame: From Baseline to Week 24 ]
    HbA1c was measured as percent of hemoglobin by a central laboratory. Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained at Week 24 in the double-blind period, including observations prior to rescue.

Secondary Outcome Measures:
  • Adjusted Mean Change From Baseline in 2-hour Post Prandial Glucose (PPG) From a Liquid Meal Tolerance Test (MTT) at Week 24 [ Time Frame: From Baseline to Week 24 ]
    Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. PPG measurements were obtained at Week 24 in the double-blind period, including observations prior to rescue.

  • Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24 [ Time Frame: From Baseline to Week 24 ]
    Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained at Week 24 in the double-blind period, including observations prior to rescue.

  • Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF]) [ Time Frame: From Baseline to Week 24 ]
    Therapeutic glycemic response is defined as HbA1c <7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.

Enrollment: 315
Study Start Date: June 2012
Study Completion Date: January 2015
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1: Saxagliptin+Dapagliflozin+Metformin IR Drug: Saxagliptin
Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
Other Name: Onglyza
Drug: Dapagliflozin
Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
Drug: Metformin IR
Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
Experimental: Arm 2: Placebo+Dapagliflozin+Metformin IR Drug: Dapagliflozin
Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
Drug: Metformin IR
Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
Drug: Placebo matching with Saxagliptin
Tablets, Oral, 0 mg, Once daily, Up to 52 weeks


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Signed Written Informed Consent

    a) Subjects must be willing and able to give signed and dated written informed consent.

  2. Target Population

    1. Subjects with T2DM with inadequate glycemic control, defined as central laboratory HbA1c ≥ 8.0 and ≤ 11.5% obtained at the screening visit (ie Week -18 visit)
    2. Stable metformin therapy for at least 8 weeks prior to screening visit at a dose ≥ 1500 mg per day.
    3. C-peptide ≥ 1.0 ng/mL (0.34 nmol/L) at screening visit.
    4. BMI ≤ 45.0 kg/m2 at the screening visit.
  3. Age and Reproductive Status

    1. Men and women, aged ≥ 18 years old at time of screening visit.
    2. Women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. See Section 3.3.3 for the definition of WOCBP.
    3. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of investigational product.
    4. Women must not be breastfeeding
    5. Sexually active fertile men must use effective birth control if their partners are WOCBP.

Exclusion Criteria

  1. Target Disease Exceptions

    1. History of diabetes insipidus
    2. Symptoms of poorly controlled diabetes that would preclude participation in this trial including but not limited to marked polyuria and polydipsia with greater than 10% weight loss during the three months prior to screening, or other signs and symptoms.
    3. History of diabetic ketoacidosis or hyperosmolar nonketotic coma.
  2. Medical History and Concurrent Diseases

    1. History of bariatric surgery or lap-band procedure within 12 months prior to screening.
    2. Any unstable endocrine, psychiatric or rheumatic disorders as judged by the Investigator.
    3. Subject who, in the judgment of the investigator, may be at risk for dehydration or volume depletion that may affect the interpretation of efficacy or safety data and concomitant use of loop diuretics in countries where this is not recommended as per the Dapagliflozin label.
    4. Subject is currently abusing alcohol or other drugs or has done so within the last 6 months.

      Acute Vascular Event:

    5. Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 160 mmHg and/or diastolic blood pressure (DBP) ≥ 100 mmHg.

      Note: Subjects with SBP ≥ 160mmHg and < 180mmHg or a DBP ≥ 100 mmHg and < 110mmHg will be able to enter the lead-in period, provided their hypertension treatment is adjusted as deemed appropriate by the investigator. These subjects cannot be randomized if their blood pressure remains with SBP ≥ 160 mmHg or DBP ≥ 100 mmHg measured at Day 1.

    6. Cardiovascular Disease within 3 months of the screening visit [ie myocardial infarction, cardiac surgery or revascularization (CABG/PTCA), unstable angina, stroke or transient ischemic attack (TIA)].
    7. Congestive heart failure as New York Association (NYHA) class IV (see Appendix 1), unstable or acute congestive heart failure. Note: eligible patients with congestive heart failure, especially those who are on diuretic therapy, should have careful monitoring of their volumes status throughout the study.

      Renal Diseases:

    8. Moderate or severe impairment of renal function [defined as eGFR < 60 mL/min/1.73 m2 (estimated by MDRD) or serum creatinine (Scr) ≥ 1.5 mg/dL in males or ≥ 1.4 mg/dL in females.]
    9. Conditions of congenital renal glucosuria

      Hepatic Diseases:

    10. Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency, including subjects with ALT and/or AST > 3x ULN and or Total Bilirubin > 2.5 x ULN.

      Hematological and Oncological Disease/Conditions

    11. History of hemoglobinopathy, with the exception of sickle cell trait (SA) or thalassemia minor; or chronic or recurrent hemolysis.
    12. Malignancy within 5 years of the screening visit (with the exception of treated basal cell or treated squamous cell carcinoma)
    13. Known immunocompromised status, including but not limited to, individuals who have undergone organ transplantation or who are positive for the human immunodeficiency virus.
    14. Donation of blood or blood products to a blood bank, blood transfusion, or participation in a clinical study requiring withdrawal of > 400 mL of blood during the 6 months prior to the screening visit.

      Prohibited treatment and therapies

    15. Administration of any antihyperglycemic therapy, other than metformin, for more than 14 days (consecutive or not) during the 12 weeks prior to screening, as well as previous participation in any DPP-4 or SGLT-2 inhibitor trial is an exclusion criterion.
    16. Current treatment with potent cytochrome P450 3A4/5 inhibitors (in countries where dose adjustment would be required by the saxagliptin label).
    17. Administration of any other investigational drug or participation in any interventional clinical studies within 30 days of planned screening to this study. Subjects who failed to satisfy all eligibility criteria at screening and did not enter the lead-in or open-label period in CV181-169 or MB102-129 studies specifically, do not need to wait 30 days.
  3. Physical and Laboratory Test Findings

    1. Hemoglobin ≤ 11.0 g/dL (110 g/L) for men; hemoglobin ≤ 10.0 g/dL (100 g/L) for women
    2. Male subjects with microscopic hematuria present at Week -18 or Week -16 AND no common cause that can be confirmed. Male subjects with a confirmed common cause can be entered into the open-label phase with a documented negative result for hematuria microscopic urinalysis performed by the central laboratory.

      NOTE: Female subjects with hematuria can be entered into the open-label phase and be randomized, but should be investigated according to local standards and best clinical practices. (See Appendix 3)

    3. Other central laboratory test findings:

      • Abnormal free T4 values. Abnormal thyroid stimulating hormone (TSH) value at screening will be further evaluated by free T4. Subjects with abnormal free T4 values will be excluded.
      • Positive for hepatitis B surface antigen
      • Positive for anti-hepatitis C virus antibody
  4. Allergies and Adverse Drug Reaction

    a) Subjects who have contraindications to therapy as outlined in the saxagliptin and dapagliflozin Investigator Brochure, the local saxagliptin or dapagliflozin package insert or the local metformin package insert, including current treatment with potent cytochrome P450 3A4/5 inhibitors (in countries where dose adjustment would be required by the local saxagliptin label).

  5. Sex and Reproductive Status

    a) Women who are pregnant

  6. Other Exclusion Criteria

    1. Prisoners or subjects who are involuntarily incarcerated.
    2. Subject who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01619059

  Hide Study Locations
United States, Alabama
University Of Alabama At Birmingham
Birmingham, Alabama, United States, 35294
Terence T. Hart, Md
Muscle Shoals, Alabama, United States, 35662
United States, Arizona
Mesa Family Medical Center
Mesa, Arizona, United States, 85203
Clinical Research Advantage Inc/Desert Clinical Research Llc
Mesa, Arizona, United States, 85213
Clinical Research Advantage, Inc
Phoenix, Arizona, United States, 85020
Clinical Research Advantage, Inc./ Stonecreek Medical Associates, Pc
Phoenix, Arizona, United States, 85028
United States, California
Beach Physicians Clinical Research Corp.
Huntington Beach, California, United States, 92647
Torrance Clinical Research
Lomita, California, United States, 90717
Randall G. Shue, Do, Inc.
Los Angeles, California, United States, 90023
National Research Institute
Los Angeles, California, United States, 90057
Cassidy Medical Group/Clinical Research Advantage
Vista, California, United States, 92083
Infosphere Clinical Research, Inc.
West Hills, California, United States, 91307
United States, Colorado
New West Physicians, Pc
Golden, Colorado, United States, 80401
United States, Florida
Southeast Clinical Research, Llc
Chiefland, Florida, United States, 32626
Clinical Therapeutics Corporation
Coral Gables, Florida, United States, 33134
Medical Research Unlimited, Llc
Hialeah, Florida, United States, 33012
University Of Florida Endocrinology & Diabetes
Jacksonville, Florida, United States, 32207
Care Partners Clinical Research, Llc
Jacksonville, Florida, United States, 32277
Clinical Research Of Miami, Inc.
Miami, Florida, United States, 33126
United States, Indiana
Clinical Research Advantage, Inc.
Evansville, Indiana, United States, 47725
Clinical Research Advantage
Evansville, Indiana, United States, 7714
United States, Missouri
Mercy Health Research
Saint Louis, Missouri, United States, 63141
United States, Nevada
Clinical Research Advantage, Inc.
Las Vegas, Nevada, United States, 89128
United States, New Hampshire
Joslin Diabetes Center Affiliate Of Snhmc
Nashua, New Hampshire, United States, 03063
United States, New York
N. Shore Diabetes & Endoc Assoc
New Hyde Park, New York, United States, 11042
Digiovanna Institute For Medical Education & Research
North Massapequa, New York, United States, 11758
United States, North Carolina
Barat Research Group, Inc.
Charlotte, North Carolina, United States, 28262
United States, Ohio
Sterling Research Grp, Ltd.
Cincinnati, Ohio, United States, 45219
Physicians Research, Inc.
Zanesville, Ohio, United States, 43701
United States, South Carolina
Tlm Medical Services
Columbia, South Carolina, United States, 29204
Family Medicine Of Sayebrook
Myrtle Beach, South Carolina, United States, 29588
United States, Tennessee
Holston Medical Group
Bristol, Tennessee, United States, 37620
Vanderbilt Diabetes Center
Nashville, Tennessee, United States, 37232
United States, Texas
Padre Coast Clinical Research
Corpus Christi, Texas, United States, 78404
Canada, New Brunswick
Local Institution
Moncton, New Brunswick, Canada, E1G 1A7
Canada, Newfoundland and Labrador
Local Institution
St-john, Newfoundland and Labrador, Canada, A1E 2E2
Canada, Nova Scotia
Local Institution
Halifax, Nova Scotia, Canada, B3K2M5
Canada, Ontario
Local Institution
Brampton, Ontario, Canada, L6T-0G1
Local Institution
Sarnia, Ontario, Canada, N7T 4X3
Canada, Quebec
Local Institution
Montreal, Quebec, Canada, H2R 1V6
Local Institution
Quebec, Canada, G3K 2P8
Czech Republic
Local Institution
Hradec Kralove, Czech Republic, 500 05
Local Institution
Karlovy Vary, Czech Republic, 360 01
Local Institution
Praha 5, Czech Republic, 150 98
Local Institution
Balatonfured, Hungary, H-8230
Local Institution
Budaors, Hungary, 2040
Local Institution
Budapest, Hungary, 1138
Local Institution
Zalaegerszeg, Hungary, 8900
Local Institution
Guadalajara, Jalisco, Mexico, 44600
Local Institution
Guadalajara, Jalisco, Mexico, 44650
Local Institution
Guadalajara, Jalisco, Mexico, 44670
Local Institution
Morelia, Michioacan, Mexico, 58070
Local Institution
Monterrey, Nuevo Leon, Mexico, 64460
Local Institution
Del. Benito Juarez, Mexico, 03100
Local Institution
Veracruz, Mexico, 91910
Local Institution
Bialystok, Poland, 15-435
Local Institution
Katowice, Poland, 40-750
Local Institution
Katowice, Poland, 40954
Local Institution
Krakow, Poland, 31-530
Local Institution
Pszczyna, Poland, 43-200
Local Institution
Pulawy, Poland, 24-100
Local Institution
Szczecin, Poland, 70-376
Local Institution
Warszawa, Poland, 01-868
Local Institution
Wegrow, Poland, 07-100
Local Institution
Wroclaw, Poland, 50-349
Puerto Rico
Research & Cardiovascular Corp
Ponce, Puerto Rico, 00717
Local Institution
Brasov, Romania, 500365
Local Institution
Bucharest, Romania, 070208
Local Institution
Bucharest, Romania, 77108
Local Institution
Bucuresti, Romania, 020045
Local Institution
Constanta, Romania, 900591
Local Institution
Craiova, Romania, 200349
Local Institution
Galati, Romania, 800098
Local Institution
Ploiesti, Romania, 100097
Russian Federation
Local Institution
Kursk, Russian Federation, 305035
Local Institution
Moscow, Russian Federation, 119034
Local Institution
Saint-petersburg, Russian Federation, 194044
Local Institution
St. Petersburg, Russian Federation, 194044
Local Institution
St. Petersburg, Russian Federation, 195257
Local Institution
St. Petersburg, Russian Federation, 197136
Local Institution
St. Petersburg, Russian Federation, 197341
Local Institution
St.petersburg, Russian Federation, 195112
Local Institution
St.petersburg, Russian Federation, 197022
Local Institution
Yaroslaval, Russian Federation, 150062
Sponsors and Collaborators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: AstraZeneca Identifier: NCT01619059     History of Changes
Other Study ID Numbers: CV181-168
2011-006323-37 ( EudraCT Number )
Study First Received: June 12, 2012
Results First Received: February 18, 2016
Last Updated: March 24, 2016

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017